Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2024-08-25 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
第六届董事会第三十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 31st meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting's attendance, the approval of the 2024 semi-annual report and related fundraising usage report, and voting results. The document does not contain the actual semi-annual report or financial statements but references where these reports can be found (on the exchange website). The document is a board meeting resolution announcement, focusing on board decisions and approvals rather than the full report itself. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management information. The document length is short (1226 characters), and it is not the report itself but an announcement of board resolutions related to reports. Hence, the classification is MANG with high confidence.
2024-08-25 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "北京星昊医药股份有限公司 2024 年半年度报告" which translates to "Beijing Sunho Pharmaceutical Co., Ltd. 2024 Semi-Annual Report." It contains detailed financial data, including income, profit, asset and liability structure, and operational analysis for the period January to June 2024. The document includes sections such as company overview, accounting data, business overview, financial analysis, and risk disclosures. It explicitly states it is a half-year report (中期报告) and contains comprehensive financial statements and management discussion. The length is about 15,000 characters, indicating a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-25 Chinese
2024年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the storage and actual use of raised funds (募集资金存放与实际使用情况的专项报告). It details the issuance of shares to qualified investors, the amount raised, the use of the funds, the balance of funds, and compliance with regulatory requirements. It includes detailed tables on fund usage, management, and investment projects. The document is not a full annual or interim financial report but a specific report on the use of capital raised through a public offering. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is over 5,000 characters and contains substantive financial data related to fundraising and fund usage, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2024-08-25 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2024 年半年度报告摘要" which translates to "2024 Semi-Annual Report Summary." It contains detailed financial data for the half-year period, including assets, liabilities, net profit, earnings per share, and other financial metrics. The document also includes business descriptions, shareholder information, and notes on asset restrictions. The length is 6848 characters, which is sufficient to contain substantive financial data and analysis. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive information. This matches the characteristics of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and contains actual financial statements and substantive financial data. It is not merely an announcement or a certification, but a report summary with financial details. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2024
2024-08-25 Chinese
第七届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the supervisory board (监事会) of Beijing Xinghao Pharmaceutical Co., Ltd. It details the convening and attendance of the 16th meeting of the 7th supervisory board, including the approval of proposals related to the 2024 semi-annual report and a special report on the use of raised funds. The document references the actual 2024 semi-annual report and related documents as being disclosed separately on the exchange website, indicating this document itself is not the report but a meeting resolution about it. The document length is short (1058 characters) and it serves as an announcement of meeting decisions rather than containing substantive financial data or the report itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2024-08-25 Chinese
国浩律师（上海）事务所关于北京星昊医药股份有限公司2024年第二次临时股东大会法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, and voting procedures of the company's 2024 second extraordinary general meeting (临时股东大会). It details the legal compliance of the meeting process, attendees' qualifications, and voting results. It does not contain financial statements, management discussion, or earnings data. It is not an announcement of voting results but a legal opinion on the meeting's legality and procedures. This type of document is related to shareholder meeting legal opinions and does not fit into categories like Annual Report, Earnings Release, or Proxy Solicitation. It is best classified under Regulatory Filings (RNS) as a legal compliance document related to corporate governance and shareholder meetings but not a direct governance report or voting result announcement.
2024-08-21 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.